Abstract

Importance: The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months of adjuvant fluoropyrimidine and oxaliplatin-based chemotherapy in patients with stage III colon cancer. The utility remains unknown. Objective: To assess the noninferiority and toxic effects of 3 vs 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjunct chemotherapy among patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial. Design, Setting, and Participants: The TOSCA study was a noninferiority phase 3 randomized clinical trial conducted from June 2007 to March 2013 in 130 Italian centers. Included patients had resected colorectal cancer located 12 cm from the anal verge by endoscopy or above the peritoneal reflection at surgery. In this preplanned study assessing the per-protocol population, 5-year relapse-free survival was evaluated in 1254 patients with high-risk stage II resected colorectal cancer who had received adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin). Interventions: Patients were originally randomized (1:1) in the TOSCA trial to receive 3 months (experimental group) or 6 months (control) of standard doses of FOLFOX or CAPOX at the discretion of the treating physician. Main Outcome and Measures: A hazard ratio of at least 1.2 between the 3-month and 6-month chemotherapy groups was set to reject the null hypothesis of noninferiority. Results: Overall, 1254 patients (mean [SD] age, 62.4 [9.8] years; 565 women [45.1%]) with clinical high-risk stage II resected colorectal cancer were analyzed at a median follow-up of 62 months (interquartile range, 53-71) months. Of them, 301 patients (24.0%) had pT4N0M0 tumors, and the remaining 953 patients (76.0%) had high-risk pT3N0M0 tumors; 776 patients (61.9%) received FOLFOX and 478 (38.1%) received CAPOX. The 5-year relapse-free survival was 82.2% for the 3-month arm and 88.2% for the 6-month arm, with an estimated hazard ratio of 1.41 (95% CI, 1.05-1.89; P =.86 for noninferiority). For CAPOX, the 5-year relapse-free survival was similar in the 2 arms (difference, 0.76% favoring the 6-month arm; 95% CI, -6.28% to 7.80%), whereas for FOLFOX, the difference was pronounced: 8.56% in favor of the longer-duration arm (95% CI, 3.45%-13.67%). Nevertheless, the test for an interaction between duration and regimen was not statistically significant. Neurotoxicity was approximately 5 times lower in the shorter duration arm than in the longer duration arm. Conclusions and Relevance: In the 3-month arm, the treatment was significantly less toxic than in the 6-month arm. Noninferiority was not shown for 5-year relapse-free survival. However, a possible regimen effect was observed, suggesting that either 3 months of CAPOX or 6 months of FOLFOX therapy can be used whenever an oxaliplatin doublet is indicated for treatment of patients with stage II colorectal cancer. Trial Registration: ClinicalTrials.gov Identifier: NCT0064660. © 2020 American Medical Association. All rights reserved.
Original languageEnglish
Pages (from-to)547-551
Number of pages5
JournalJAMA Oncol.
Volume6
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • capecitabine
  • fluorouracil
  • folinic acid
  • oxaliplatin
  • antineoplastic agent
  • platinum complex
  • adjuvant chemotherapy
  • adult
  • adverse outcome
  • allergic reaction
  • Article
  • cancer staging
  • clinical effectiveness
  • colorectal cancer
  • controlled study
  • diarrhea
  • digestive tract endoscopy
  • drug effect
  • drug efficacy
  • drug response
  • female
  • follow up
  • high risk patient
  • human
  • Italy
  • major clinical study
  • male
  • middle aged
  • multicenter study
  • neuropathy
  • neutropenia
  • phase 3 clinical trial
  • randomized controlled trial
  • recurrence free survival
  • survival rate
  • treatment duration
  • treatment outcome
  • trend study
  • adverse event
  • aged
  • child
  • clinical trial
  • colorectal tumor
  • disease free survival
  • pathology
  • preschool child
  • tumor recurrence
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Capecitabine
  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Colorectal Neoplasms
  • Disease-Free Survival
  • Female
  • Fluorouracil
  • Humans
  • Leucovorin
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Organoplatinum Compounds
  • Oxaliplatin

Fingerprint Dive into the research topics of 'Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this